149 related articles for article (PubMed ID: 38082520)
1. [Moderne Diagnostik und Therapie des Merkelzellkarzinoms].
Weilandt J; Peitsch WK
J Dtsch Dermatol Ges; 2023 Dec; 21(12):1524-1548. PubMed ID: 38082520
[TBL] [Abstract][Full Text] [Related]
2. Modern diagnostics and treatment of Merkel cell carcinoma.
Weilandt J; Peitsch WK
J Dtsch Dermatol Ges; 2023 Dec; 21(12):1524-1546. PubMed ID: 37875785
[TBL] [Abstract][Full Text] [Related]
3. Recent Therapeutic Advances and Change in Treatment Paradigm of Patients with Merkel Cell Carcinoma.
Garcia-Carbonero R; Marquez-Rodas I; de la Cruz-Merino L; Martinez-Trufero J; Cabrera MA; Piulats JM; Capdevila J; Grande E; Martin-Algarra S; Berrocal A
Oncologist; 2019 Oct; 24(10):1375-1383. PubMed ID: 30962295
[TBL] [Abstract][Full Text] [Related]
4. [Das kutane Plattenepithelkarzinom: Aktueller Stand, Perspektiven und offene Fragen].
Heppt MV; Leiter U
J Dtsch Dermatol Ges; 2023 Apr; 21(4):421-425. PubMed ID: 37070515
[TBL] [Abstract][Full Text] [Related]
5. Merkel Cell Carcinoma.
Lewis DJ; Sobanko JF; Etzkorn JR; Shin TM; Giordano CN; McMurray SL; Walker JL; Zhang J; Miller CJ; Higgins HW
Dermatol Clin; 2023 Jan; 41(1):101-115. PubMed ID: 36410971
[TBL] [Abstract][Full Text] [Related]
6. An Updated Review of the Biomarkers of Response to Immune Checkpoint Inhibitors in Merkel Cell Carcinoma: Merkel Cell Carcinoma and Immunotherapy.
Fojnica A; Ljuca K; Akhtar S; Gatalica Z; Vranic S
Cancers (Basel); 2023 Oct; 15(20):. PubMed ID: 37894451
[TBL] [Abstract][Full Text] [Related]
7. Sequenzielles Auftreten einer primären und sekundären Hypothyreose unter Therapie mit Nivolumab: Fallstricke in der immunonkologischen Therapie und endokrinologischen Diagnostik.
Ansorge C; Seufert J; Meiss F; von Bubnoff D
J Dtsch Dermatol Ges; 2018 Dec; 16(12):1483-1485. PubMed ID: 30537309
[No Abstract] [Full Text] [Related]
8. Merkel cell carcinoma: epidemiology, clinical features, diagnosis and treatment of a rare disease.
Siqueira SOM; Campos-do-Carmo G; Dos Santos ALS; Martins C; de Melo AC
An Bras Dermatol; 2023; 98(3):277-286. PubMed ID: 36870886
[TBL] [Abstract][Full Text] [Related]
9. S2k-Leitlinie zur Diagnostik und Therapie des kutanen Lupus erythematodes - Teil 2: Therapie, Risikofaktoren und spezielle Fragestellungen.
Worm M; Zidane M; Eisert L; Fischer-Betz R; Foeldvari I; Günther C; Iking-Konert C; Kreuter A; Müller-Ladner U; Nast A; Ochsendorf F; Schneider M; Sticherling M; Tenbrock K; Wenzel J; Kuhn A
J Dtsch Dermatol Ges; 2021 Sep; 19(9):1371-1395. PubMed ID: 34541800
[No Abstract] [Full Text] [Related]
10. Immune evasion mechanisms and immune checkpoint inhibition in advanced merkel cell carcinoma.
Schadendorf D; Nghiem P; Bhatia S; Hauschild A; Saiag P; Mahnke L; Hariharan S; Kaufman HL
Oncoimmunology; 2017; 6(10):e1338237. PubMed ID: 29123950
[TBL] [Abstract][Full Text] [Related]
11. [S3-Leitlinie "Aktinische Keratose und Plattenepithelkarzinom der Haut" - Update 2023, Teil 2: Epidemiologie und Ätiologie, Diagnostik, Therapie des invasiven Plattenepithelkarzinoms der Haut, Nachsorge und Prävention: S3 guideline "actinic keratosis and cutaneous squamous cell carcinoma" - update 2023, part 2: epidemiology and etiology, diagnostics, surgical and systemic treatment of cutaneous squamous cell carcinoma (cSCC), surveillance and prevention].
Leiter U; Heppt MV; Steeb T; Alter M; Amaral T; Bauer A; Bechara FG; Becker JC; Breitbart EW; Breuninger H; Diepgen T; Dirschka T; Eigentler T; El Gammal AKS; Felcht M; Flaig MJ; Follmann M; Fritz K; Grabbe S; Greinert R; Gutzmer R; Hauschild A; Hillen U; Ihrler S; John SM; Kofler L; Koelbl O; Krause-Bergmann A; Kraywinkel K; Krohn S; Langer T; Loquai C; Löser CR; Mohr P; Nashan D; Nothacker M; Pfannenberg C; Salavastru C; Schmitz L; Stockfleth E; Szeimies RM; Ulrich C; Voelter-Mahlknecht S; Vordermark D; Weichenthal M; Welzel J; Wermker K; Wiegand S; Garbe C; Berking C
J Dtsch Dermatol Ges; 2023 Nov; 21(11):1422-1434. PubMed ID: 37946644
[TBL] [Abstract][Full Text] [Related]
12. [Immune checkpoint inhibition in Merkel cell carcinoma].
Terheyden P; Mohr A; Langan EA
Hautarzt; 2019 Sep; 70(9):684-690. PubMed ID: 31468071
[TBL] [Abstract][Full Text] [Related]
13. Ipilimumab plus nivolumab in avelumab-refractory Merkel cell carcinoma: a multicenter study of the prospective skin cancer registry ADOREG.
Glutsch V; Schummer P; Kneitz H; Gesierich A; Goebeler M; Klein D; Posch C; Gebhardt C; Haferkamp S; Zimmer L; Becker JC; Leiter U; Weichenthal M; Schadendorf D; Ugurel S; Schilling B
J Immunother Cancer; 2022 Nov; 10(11):. PubMed ID: 36450381
[TBL] [Abstract][Full Text] [Related]
14. Avelumab and other recent advances in Merkel cell carcinoma.
Bommareddy PK; Kaufman HL
Future Oncol; 2017 Dec; 13(30):2771-2783. PubMed ID: 28976209
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and toxicity of immune checkpoint inhibitors combination therapy for advanced renal cell carcinoma: a systematic review and network meta-analysis.
Chen X; Xu Z; Wu C; Xie L; Wang P; Liu X
Front Immunol; 2024; 15():1255577. PubMed ID: 38390328
[TBL] [Abstract][Full Text] [Related]
16. Caring for Patients Treated With Checkpoint Inhibitors for the Treatment of Metastatic Merkel Cell Carcinoma.
Rubin KM; Hoffner B; Bullock AC
Semin Oncol Nurs; 2019 Oct; 35(5):150924. PubMed ID: 31514991
[TBL] [Abstract][Full Text] [Related]
17. PD-L1 inhibition with avelumab for metastatic Merkel cell carcinoma.
Gaiser MR; Bongiorno M; Brownell I
Expert Rev Clin Pharmacol; 2018 Apr; 11(4):345-359. PubMed ID: 29478343
[TBL] [Abstract][Full Text] [Related]
18. T-Cell Responses in Merkel Cell Carcinoma: Implications for Improved Immune Checkpoint Blockade and Other Therapeutic Options.
Gehrcken L; Sauerer T; Schaft N; Dörrie J
Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445385
[TBL] [Abstract][Full Text] [Related]
19. Single administration of avelumab induced a complete response in thyroid transcription factor 1-positive combined Merkel cell carcinoma.
Kanemaru H; Fukushima S; Mizukami Y; Sawamura S; Nakamura K; Honda N; Makino K; Kajihara I; Aoi J; Makino T; Kawasaki T; Kudou E; Jhono M; Ito T; Arima N; Ihn H
J Dermatol; 2020 Nov; 47(11):1317-1321. PubMed ID: 32794263
[TBL] [Abstract][Full Text] [Related]
20. [Personalized medicine in the treatment of periocular tumors : Targeted treatment and use of immune checkpoint inhibitors].
Rokohl AC; Koch KR; Mor JM; Loreck N; Schlaak M; Mauch C; Bechrakis NE; Mohi A; Kakkassery V; Heindl LM
Ophthalmologe; 2020 Jun; 117(6):521-527. PubMed ID: 31938823
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
